What is Gyre Therapeutics, Inc.'s debt issuance costs?

Gyre Therapeutics, Inc. (GYRE) reported debt issuance costs of $1.68M in Q2 2025.

What does debt issuance costs mean?

Cash paid for fees, legal costs, and underwriting discounts associated with issuing new debt.

Gyre Therapeutics, Inc. GYRE Debt Issuance Costs

Debt Issuance Costs at other companies

Ligand PharmaceuticalsLGND

$50K-29.6%

BridgeBio PharmaBBIO

——

Other financials

Income statement

See full

Revenue$22.5M+2.1%

Gross profit$21.3M+0.6%

Operating income-$9.4M-512%

Net income-$8.7M-422%

EPS (diluted)-$0.10—

Balance sheet

See full

Cash & equivalents$37.5M+149%

Total debt$823.0K-48.1%

Total equity$101.3M+48.7%

Total assets$162.0M+24.8%

Cash flow

See full

Operating cash flow$3.2M+2,565%

CapEx$178.0K+45.9%

Free cash flow$3.0M+1,296%

Valuation

See full

Market cap$694.58M-4.7%

Enterprise value$657.9M-8.0%

P/S5.9×-1.3×

Profitability

See full

Gross margin95.1%-1.1pp

Operating margin-0.1%-10.4pp

Net margin6.3%+3.3pp

FCF margin2.6%—

Returns & leverage

See full

Return on equity8.2%+4.2pp

Debt / equity0×0.0×

Current ratio4.6×+1.0×

Where this comes from

Reported directly by Gyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfFinancingCosts.

The official record: Gyre Therapeutics, Inc.’s 10-Q, filed August 11, 2025, on SEC EDGAR. View the filing →

Ask your AI about Gyre Therapeutics, Inc.'s debt issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Gyre Therapeutics, Inc.'s debt issuance costs?: Gyre Therapeutics, Inc. (GYRE) reported debt issuance costs of $1.68M in Q2 2025.
What does debt issuance costs mean?: Cash paid for fees, legal costs, and underwriting discounts associated with issuing new debt.